Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory pH monitoring study of sodium alginate oral suspension versus placebo in healthy volunteers
NL-OMON41075Phase 2Active, not recruiting
- Sponsor
- Reckitt
- Start
- Oct 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Sodium alginate and calcium carbonate + magnesium carbonate in gastroesophageal reflux disease (GERD) (2 cohorts), sponsored by Reckitt. Started Oct 2014; status: active, not recruiting.
02
Drugs
Sodium alginatecalcium carbonate + magnesium carbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NL-OMON41075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41075.